Subscribe To
Aravive to host virtual kol event on its late-stage oncology asset batiraxcept
Webinar to take place on Wednesday, May 24, 2023 at 1:00pm ET HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV, “the Company�...
May 8, 2023, 11:05 am
Aravive announces poster presentation on batiraxcept at 2023 asco annual meeting
HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing target...
April 26, 2023, 9:00 pm
Aravive to present positive updated data from phase 1b trial of batiraxcept in combination with cabozantinib for treatment of clear cell renal cell carcinoma at the 2023 asco genitourinary (gu) cancer
HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted...
February 13, 2023, 5:00 pm
Aravive to present positive updated data from phase 1b trial of batiraxcept in combination with cabozantinib for treatment of clear cell renal cell carcinoma at the 2023 asco genitourinary (gu) cancer
HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted...
February 13, 2023, 5:00 pm
Aravive to present positive updated data from phase 1b trial of batiraxcept in combination with cabozantinib for treatment of clear cell renal cell carcinoma at the 2023 asco genitourinary (gu) cancer
HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted...
February 13, 2023, 5:00 pm
Aravive: down but not out with pivotal ovarian data due in 2023
Aravive shareholders have been heavily diluted and suffered substantial losses in 2022. The company has struggled for cash, but now says it has funds ...
December 14, 2022, 8:45 am
Aravive highlights updated batiraxcept data from kidney cancer trial
Aravive Inc (NASDAQ: ARAV) has announced new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of ...
March 3, 2022, 10:06 am
Aravive highlights updated batiraxcept data from kidney cancer trial
Aravive Inc (NASDAQ: ARAV) has announced new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of ...
March 3, 2022, 10:06 am
Aravive highlights updated batiraxcept data from kidney cancer trial
Aravive Inc (NASDAQ: ARAV) has announced new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of ...
March 3, 2022, 10:06 am